|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
Exhibit Number
|
Description
|
99.1
|
22
March 2024 - “Holding(s) in Company”
|
GB00BMX86B70
|
HALEON
PLC
|
UK
|
An
acquisition or disposal of voting rights
|
Pfizer
Inc.
|
New
York
|
United
States of America
|
Name
|
City
of registered office
|
Country
of registered office
|
Guaranty Nominees
Limited
|
London
|
United
Kingdom
|
BofA
Securities, Inc.
|
Wilmington,
Delaware
|
United
States of America
|
21-Mar-2024
|
21-Mar-2024
|
..
|
%
of voting rights attached to shares (total of 8.A)
|
%
of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights held in issuer
|
Resulting situation
on the date on which threshold was crossed or reached
|
22.580000
|
0.000000
|
22.580000
|
2062236079
|
Position of
previous notification (if applicable)
|
32.000000
|
0.000000
|
32.000000
|
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
Ordinary Shares
GB00BMX86B70
|
|
1667778175
|
|
18.260000
|
Restricted
ADSs
|
|
394457904
|
|
4.320000
|
Sub
Total 8.A
|
2062236079
|
22.580000%
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
1.
Person subject to the notification obligation is not controlled by
any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer.
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
This
notification relates to the sale by Pfizer Inc. ("Pfizer") of a
portion of its interest in Haleon plc ("Haleon").
|
|
Pfizer
sold 594,000,000 Haleon ordinary shares and 196,554,820 ordinary
shares in the form of American depositary shares, each representing
two ordinary shares ("ADSs") pursuant to a global offer. In
connection with the global offer, Haleon repurchased 102,272,727
ordinary shares from Pfizer in accordance with the terms of a share
purchase deed between Haleon and Pfizer dated 11 September 2023 and
approved by Haleon’s shareholders at its annual general
meeting on 20 April 2023.
|
These
calculations are based on an issued share capital of Haleon of
9,132,301,104 ordinary shares, following cancellation of the
102,272,727 ordinary shares repurchased from Pfizer, as
communicated by Haleon in their announcement on total voting rights
and capital dated 21 March 2024.
|
Pfizer
holds its ordinary shares in Haleon through (i) BofA Securities,
Inc., and (ii) Guaranty Nominees Limited (in respect of the ADSs),
which hold the legal title to those shares on Pfizer's
behalf.
|
21-Mar-2024
|
New
York, USA
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
March 22, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|